Saccharomyces Boulardii: What the Trials Show, the Doses Used, and Who – Agape Nutrition
Left Continue shopping
Your Order

You have no items in your cart

Amber supplement bottle and a petri dish of yeast colonies on an oak table holding Saccharomyces boulardii.

Saccharomyces Boulardii: What the Trials Show, the Doses Used, and Who Should Avoid It

Saccharomyces boulardii is one of the few probiotics with a real clinical file behind it. It is a yeast, not a bacterium, so it behaves differently from the Lactobacillus and Bifidobacterium strains most people picture. That difference is why it can be taken alongside antibiotics, and why it deserves a closer look than a generic capsule.

The research is useful and uneven. The strongest evidence sits in prevention of antibiotic-associated diarrhea. The weakest sits in treating diarrhea that has already started. In between are H. pylori treatment support, traveler's diarrhea, and a thin but promising IBS signal.

This guide separates those categories, gives the doses that were tested, explains what the numbers mean, and covers the safety points that matter. The short version: this yeast has a place, and the place is narrower than the marketing suggests.

Table of contents

What Saccharomyces boulardii actually is

Saccharomyces boulardii is a non-pathogenic yeast. That single fact explains most of its behavior. Antibiotics target bacteria, so they do not kill it, and it can pass through an antibiotic course while the bacterial population shifts [11].

The most studied strain is Saccharomyces boulardii CNCM I-745, formerly known as ATCC 74012. It is now classified as a variant of Saccharomyces cerevisiae, the same species as baker's yeast, though it behaves very differently in the gut. Other commercial strains exist, including DBVPG 6763 and several proprietary strains. That detail matters later.

It is also transient. It does not take up residence in your gut. Stool levels fall after you stop, and it is generally cleared within about a week [1]. This is not a one-time fix that permanently changes your microbiome. It is more like a temporary worker who shows up during a disruption and then leaves.

The mechanisms are mostly about interference and support. Research points to inhibition of bacterial toxins, competitive exclusion, production of antimicrobial peptides, immune modulation, and trophic effects on the intestinal brush border [9][22]. Other work focuses on the intestinal barrier, the line between gut contents and the bloodstream [10]. In plain terms, it helps the gut environment hold its shape during stress.

For background on how different probiotics fit together, the digestion and gut health pillar is a good starting point.

Illustration of the small intestine lining with beneficial Saccharomyces boulardii yeast cells along the mucosal surface.
Saccharomyces boulardii is a transient yeast that works along the intestinal lining while it is being taken.

What the evidence supports, and what it does not

The evidence splits by use, by population, and by whether you are preventing a problem or treating one. The table below summarizes it, and the sections after it explain the numbers.

Use What the evidence shows Strength
Antibiotic-associated diarrhea, prevention Consistent reduction across trials Strongest
Antibiotic-associated diarrhea, elderly hospitalized No benefit in a dedicated trial of 275 elderly hospitalized adults Negative
Acute infectious diarrhea, treatment No clear benefit in low-risk-of-bias trials Negative overall
H. pylori eradication, adjunct Modest improvement plus fewer side effects Moderate
Traveler's diarrhea, prevention Lower incidence in older trials Limited
IBS symptoms Small pilot improvements Weak
C. difficile prevention Recurrence signal, underpowered Unclear

Antibiotic-associated diarrhea: the strongest case

This is where the case is clearest. A meta-analysis of 27 trials and 5,029 adults found that S. boulardii was associated with a lower risk of antibiotic-associated diarrhea, with a risk ratio of 0.47 [1]. A risk ratio of 0.47 means the treated group had about half the risk of the control group. The number needed to treat was about 10, so roughly one case was prevented for every 10 people treated.

A Cochrane review in children found a similar direction for probiotics as a group: diarrhea occurred in 8% of the probiotic group versus 19% of controls, with a risk ratio of 0.45 and a number needed to treat for benefit of 9 [2]. That review pooled several probiotics, so read it as supporting context, not a strain-specific result. ESPGHAN, the European pediatric gastroenterology society, issued a strong recommendation for S. boulardii for prevention in children, based on moderate quality evidence [3][17].

Then comes the counterweight. A randomized trial in 275 elderly hospitalized adults started S. boulardii within 48 hours of antibiotics and continued for 7 days after. Diarrhea occurred in 15.1% of the S. boulardii group and 13.3% of the placebo group, with an odds ratio of 1.16 [14]. An odds ratio above 1 means the treated group had slightly higher odds, and the confidence interval crossed 1, so the trial found no benefit. The effect is not uniform across every population.

Acute infectious diarrhea: the honest caveat

This is where marketing often overreaches. A 2020 Cochrane review of 82 trials and 12,127 participants, mostly children, looked at probiotics for treating acute infectious diarrhea. In the trials at low risk of bias, there was no difference in whether diarrhea lasted 48 hours or more, with a risk ratio of 1.00 [4]. A risk ratio of 1.00 means the two groups were essentially identical. Duration was 8.64 hours shorter on average, but the confidence interval ran from 29.4 hours shorter to 12.1 hours longer, with very low certainty. Subgroup analyses including S. boulardii did not change the picture.

One small pediatric trial did show benefit: 250 mg twice daily for 5 days in children aged 3 to 59 months reduced mean diarrhea duration from 64.0 to 52.1 hours, and time to first semi-formed stool from 54.1 to 39.5 hours [21]. That is a single small trial, and it does not overturn the pooled result. Prevention and treatment are different questions, and the strong answers are on the prevention side.

H. pylori treatment support

Here the evidence is about support, not replacement. A meta-analysis of 18 trials and 3,592 patients found that adding S. boulardii to standard eradication therapy was associated with a higher eradication rate, with a risk ratio of 1.09 [5]. That means about a 9% relative improvement in the chance of successful eradication. Total side effects fell with a risk ratio of 0.47, diarrhea with 0.33, and constipation with 0.37.

A 2025 meta-analysis of 10 randomized trials found a similar pattern: eradication risk ratio 1.08, total adverse effects 0.53, and diarrhea 0.28 [6]. A risk ratio of 0.28 for diarrhea means the treated group had about 28% of the diarrhea risk of the control group. Both 500 mg per day and 1,000 mg per day worked in subgroup analysis, and the best results came from starting and stopping with the eradication course and continuing for more than 10 days. None of this replaces antibiotics. If you are being treated for H. pylori, this is a conversation to have with your clinician, and our overview of H. pylori treatment approaches can help you ask better questions.

Traveler's diarrhea

The traveler's data is older and less robust. Trials used 250 to 1,000 mg per day, started about 5 days before travel and continued during the trip, roughly 3 weeks. Diarrhea incidence was 29% to 34% with S. boulardii versus 39% to 43% with placebo [1]. One larger trial reported a dose-dependent reduction. Supportive, not definitive.

IBS and SIBO

The IBS evidence is weak but not empty. McFarland's review cites a small trial using 9 billion CFU per day for 4 weeks, with 87.5% of the S. boulardii group reporting improvement versus 72% on placebo [1]. A 2023 randomized open-label pilot enrolled 54 people with diarrhea-predominant IBS and bacterial overgrowth (48 were evaluated) and found that 15 days of S. boulardii plus dietary advice reduced the IBS symptom severity score by 134 points versus 93 with dietary advice alone. Diarrhea was reported in 25.9% versus 47.6%, and hydrogen excretion fell 41% versus 29% [19]. That is a small, open-label pilot, so treat it as a signal worth watching, not proof. If SIBO relapse is your context, our article on SIBO relapse prevention goes deeper.

C. difficile

A systematic review of 4 trials found a recurrence prevention signal, with risk ratios of 0.53 in one trial and a trend toward 0.33 in another that used high-dose vancomycin [15]. The primary prevention trials were underpowered. S. boulardii is not a treatment for active C. difficile infection and does not replace antibiotics. The AGA's 2020 technical review makes the broader point that probiotic evidence is strain-specific and disease-specific, so pooling different strains can mislead [20].

Two petri dishes comparing round yeast colonies with tiny bacterial colonies, illustrating that Saccharomyces boulardii is a yeast.
Saccharomyces boulardii is a yeast, not a bacterium, which is why antibiotics do not kill it.

The doses used in the trials

Doses in the research are not a prescription. They are the amounts tested, in specific populations, for specific periods. Use them to compare products and to guide a conversation with your clinician.

Use Trial dose Notes
AAD prevention, adults 500-1,000 mg/day 200-1,000 mg/day tested; through the antibiotic course and beyond
Traveler's diarrhea 250-1,000 mg/day Started 5 days before travel, continued during the trip
H. pylori adjunct 500-1,000 mg/day 2025 meta-analysis recommended 500 mg/day with a course over 10 days
Pediatric acute diarrhea 250 mg twice daily for 5 days Single small trial
IBS 9 billion CFU/day for 4 weeks Weak evidence, single small trial

A rough conversion helps when a label lists milligrams instead of CFU. In the trial literature, 200 mg was about 4 billion CFU and 1,000 mg was about 20 billion CFU [1]. On that basis, 500 mg is roughly 10 billion CFU. Check what the label states, since the conversion is not universal.

For AAD prevention, trials ran 6 to 14 days or through the antibiotic course plus 3 days to 2 weeks [1]. The commonly recommended range is 500 to 1,000 mg per day. A review of dose responses found a positive relationship between dose and risk reduction, which suggests higher doses may matter, but it does not establish a precise threshold [16].

For H. pylori, the 2025 meta-analysis found that both 500 mg and 1,000 mg per day were associated with higher eradication rates, and it recommended 500 mg per day alongside a course longer than 10 days [6]. McFarland's earlier review lists 1,000 mg per day for H. pylori symptom support [1]. For children with acute diarrhea, the single trial used 250 mg twice daily for 5 days [21]. For IBS, the small trial used 9 billion CFU per day for 4 weeks [1].

Saccharomyces boulardii supplement bottle with a glass of water on a warm apothecary table.
Trial doses are listed in milligrams and CFU. Check which one your label uses before comparing products.

How to take it with antibiotics and antifungals

The antibiotic question has a clean answer. Antibiotics do not kill S. boulardii because it is a yeast, not a bacterium. You do not need to separate the doses the way you might with a bacterial probiotic. Some clinicians still suggest spacing them, and that is reasonable, but the more important rule is consistency.

Timing in the trials is a useful guide. In the AAD prevention trials, S. boulardii started with the antibiotic course or within 48 hours of the first dose, and continued for 3 days to 2 weeks after the antibiotics stopped [1]. The elderly trial that found no benefit started within 48 hours and continued 7 days after [14]. The window is early, and the tail matters.

Antifungals are different. Antifungals can reduce the viability of S. boulardii. Many product labels and clinicians recommend separating the doses by at least 4 hours, so ask your pharmacist or clinician about timing.

For H. pylori treatment, the 2025 analysis found that starting and stopping S. boulardii with the eradication course worked best, and that a course longer than 10 days improved results [6]. For travel, the trials started about 5 days before departure and continued during the trip [1].

A few practical points:

  • Take it at a time you will remember, because consistency matters more than the perfect minute.
  • If you are on antibiotics, start at the beginning of the course rather than partway through.
  • If you are on an antifungal, ask your clinician or pharmacist about spacing the doses.
  • Finish the planned course rather than stopping on the first good day.

If you are rebuilding after antibiotics, our guide to gut health after antibiotics covers the wider picture, including food and fiber.

Side effects and who should avoid it

Most people tolerate S. boulardii well. In the 2,963 adults across the trials in McFarland's review, the only adverse effects attributed to it were thirst in 5 people and constipation in 8 people in a C. difficile trial [1].

But rare fungemia is real, and it is the reason this is not a risk-free product. A Finnish study covering 2009 to 2018 identified 46 patients with Saccharomyces fungemia. At least 20 of them, or 43%, were using S. boulardii. The odds ratio for probiotic use compared with controls who had bacteremia or candidemia was 14, with a confidence interval of 4 to 44 [7]. An odds ratio of 14 is a strong association, even though the absolute number of cases is small. In a separate analysis of 1,153 non-blood culture findings, 125 histories were checked and at least 24, or 19%, were using the probiotic, with an odds ratio of 10 [7].

There is also a case report of strain-matched fungemia in an immunocompetent patient after S. boulardii, confirmed by genomic and proteomic typing [8]. That detail matters: the risk is not confined to people with obvious immune compromise.

Ask a clinician first, or avoid it, if you:

  • Critically ill or hospitalized with severe illness
  • Immunocompromised or immunosuppressed
  • Central venous catheter or implanted port
  • Premature infant
  • Yeast allergy
  • Pregnant or breastfeeding, because safety data are insufficient

Stop and seek medical advice if you develop fever, chills, symptoms of a bloodstream infection, or severe abdominal symptoms. The transient nature of the yeast is relevant here too. It clears within about a week after you stop [1]. That is useful to know, but it is not a reason to ignore symptoms.

How to choose a product that matches the evidence

The label is where most of the decision gets made. Strain matters, because the efficacy data are strain-specific and disease-specific [12][13][20]. The strain used in most of the trials discussed here is CNCM I-745. A product that says only "Saccharomyces boulardii" may contain a different strain, such as DBVPG 6763, and the trial results do not automatically transfer.

If a product does not name a strain, you cannot tell which one you are getting.

A practical checklist:

  • Full strain name on the label, for example CNCM I-745 or DBVPG 6763.
  • CFU at expiry, not just at manufacture, where the label states it.
  • A milligram amount you can compare with the trial doses above.
  • Lactose-free if you need it. Check the label, since formulations vary.
  • Storage instructions that match how you will keep it.
  • Third-party verification where available. Certification is a reasonable trust signal, but not every manufacturer uses it [18].

Quality varies, and certification is not universal [18]. That is a reason to read the label rather than the front of the box. Our guides to choosing a probiotic and reading a supplement label walk through the details.

At Agape Nutrition, the catalog is curated around practitioner-grade brands, and the team can help you compare strain names and CFU counts before you buy. You can browse the digestion and gastrointestinal support collection to see what is available.

What We Recommend

These are products Agape Nutrition stocks, not a ranking, and this article does not name a best buy: matching the strain on the label to the strain in the evidence matters more than the brand.

XYMOGEN, ProbioMax Sb DF 60 Capsules

A four-strain probiotic that includes S. boulardii plus B. lactis HN019, in gastro-resistant capsules.

$84.99

XYMOGEN, Saccharomycin DF 60 Capsules

A lactose-free, stomach acid resistant S. boulardii with 10 billion CFU per 2-capsule dose.

$58.99

Allergy Research Group, Essential-Biotic Saccharomyces Boulardii 60 Veg Capsules

A single-strain S. boulardii (DBVPG 6763) with 9 billion CFU per 3-capsule serving.

DBVPG 6763 is a different strain from the CNCM I-745 used in most of the trials discussed above.

$28.89

Frequently asked questions

Is Saccharomyces boulardii a probiotic?

Yes, but it is a yeast rather than a bacterium. That distinction explains why antibiotics do not kill it and why it can be taken during an antibiotic course. It is still a living organism, so the same quality and safety questions apply.

How much Saccharomyces boulardii should I take daily?

The tested doses range from 200 to 1,000 mg per day for antibiotic-associated diarrhea prevention, with 500 to 1,000 mg per day being the common range [1]. H. pylori trials used 500 mg or 1,000 mg per day, and the 2025 meta-analysis recommended 500 mg per day [6]. These are trial doses, not a personal prescription.

Can you take Saccharomyces boulardii with antibiotics?

Yes. Antibiotics target bacteria and do not kill this yeast, so separation is not required [1]. Start early in the antibiotic course and continue for a few days to two weeks after it ends. If you also take an antifungal, ask your clinician or pharmacist about spacing the doses.

Does Saccharomyces boulardii help with diarrhea?

It depends on the type. The evidence is strongest for preventing antibiotic-associated diarrhea, with a risk ratio of 0.47 in a large meta-analysis [1]. For treating acute infectious diarrhea that has already started, a 2020 Cochrane review found no clear benefit in low-risk-of-bias trials [4].

What is the difference between Saccharomyces boulardii and Lactobacillus?

S. boulardii is a yeast and Lactobacillus is a bacterium. Antibiotics kill many Lactobacillus strains, while S. boulardii survives them. The evidence for each is strain-specific, so a result for one does not automatically apply to the other [13].

How long does Saccharomyces boulardii stay in your system?

It is transient and does not colonize the gut permanently. Stool levels fall after you stop, and it is generally cleared within about a week [1]. That is why it is taken daily during the period you want the effect.

Who should not take Saccharomyces boulardii?

People who are critically ill, immunocompromised, or have a central line or port should avoid it or ask a clinician first [7]. The same applies to premature infants, people with a yeast allergy, and anyone pregnant or breastfeeding. Rare fungemia has been reported, including in an immunocompetent patient [8].

Is Saccharomyces boulardii safe for children?

It is generally well tolerated, and ESPGHAN recommends it for antibiotic-associated diarrhea prevention in children [3]. A small trial used 250 mg twice daily for 5 days in acute diarrhea [21]. Ask a pediatric clinician before starting, especially for infants or children with serious health conditions.

References

  1. McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 2010;16(18):2202-2222. https://pubmed.ncbi.nlm.nih.gov/20458757/
  2. Guo Q, Goldenberg JZ, Humphrey C, El Dib R, Johnston BC. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2019;4:CD004827. https://pubmed.ncbi.nlm.nih.gov/31039287/
  3. Szajewska H, Canani RB, Guarino A, et al. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. J Pediatr Gastroenterol Nutr. 2016;62(3):495-506. https://pubmed.ncbi.nlm.nih.gov/26756877/
  4. Collinson S, Deans A, Padua-Zamora A, et al. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 2020;12:CD003048. https://pubmed.ncbi.nlm.nih.gov/33295643/
  5. Zhou BG, Chen LX, Li B, Wan LY, Ai YW. Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: a systematic review and meta-analysis with trial sequential analysis. Helicobacter. 2019;24(5):e12651. https://pubmed.ncbi.nlm.nih.gov/31414551/
  6. Jiang YZ, Ma K, Cui C, Li ZY, Wang XY. Effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on Helicobacter pylori eradication. BMC Gastroenterol. 2025;25:273. https://pubmed.ncbi.nlm.nih.gov/40251486/
  7. Rannikko J, Holmberg V, Karppelin M, et al. Fungemia and Other Fungal Infections Associated with Use of Saccharomyces boulardii Probiotic Supplements. Emerg Infect Dis. 2021;27(8):2090-2096. https://pubmed.ncbi.nlm.nih.gov/34287140/
  8. Martin IW, Tonner R, Trivedi J, et al. Saccharomyces boulardii probiotic-associated fungemia: questioning the safety of this preventive probiotic's use. Diagn Microbiol Infect Dis. 2017;87(3):286-288. https://pubmed.ncbi.nlm.nih.gov/28024866/
  9. Pais P, Almeida V, Yilmaz M, Teixeira MC. Saccharomyces boulardii: What Makes It Tick as Successful Probiotic? J Fungi (Basel). 2020;6(2):78. https://pubmed.ncbi.nlm.nih.gov/32512834/
  10. Terciolo C, Dapoigny M, Andre F. Beneficial effects of Saccharomyces boulardii CNCM I-745 on clinical disorders associated with intestinal barrier disruption. Clin Exp Gastroenterol. 2019;12:67-82. https://pubmed.ncbi.nlm.nih.gov/30804678/
  11. Waitzberg D, Guarner F, Hojsak I, et al. Can the Evidence-Based Use of Probiotics (Notably Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG) Mitigate the Clinical Effects of Antibiotic-Associated Dysbiosis? Adv Ther. 2024;41(3):901-914. https://pubmed.ncbi.nlm.nih.gov/38286962/
  12. Sniffen JC, McFarland LV, Evans CT, Goldstein EJC. Choosing an appropriate probiotic product for your patient: An evidence-based practical guide. PLoS One. 2018;13(12):e0209205. https://pubmed.ncbi.nlm.nih.gov/30586435/
  13. McFarland LV, Evans CT, Goldstein EJC. Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2018;5:124. https://pubmed.ncbi.nlm.nih.gov/29868585/
  14. Pozzoni P, Riva A, Bellatorre AG, et al. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol. 2012;107(6):922-931. https://pubmed.ncbi.nlm.nih.gov/22472744/
  15. Tung JM, Dolovich LR, Lee CH. Prevention of Clostridium difficile infection with Saccharomyces boulardii: a systematic review. Can J Gastroenterol. 2009;23(12):817-821. https://pubmed.ncbi.nlm.nih.gov/20011734/
  16. Ouwehand AC. A review of dose-responses of probiotics in human studies. Benef Microbes. 2017;8(2):143-151. https://pubmed.ncbi.nlm.nih.gov/28008787/
  17. Yang Q, Hu Z, Lei Y, et al. Overview of systematic reviews of probiotics in the prevention and treatment of antibiotic-associated diarrhea in children. Front Pharmacol. 2023;14:1153070. https://pubmed.ncbi.nlm.nih.gov/37564180/
  18. Jackson SA, Schoeni JL, Vegge C, et al. Improving End-User Trust in the Quality of Commercial Probiotic Products. Front Microbiol. 2019;10:739. https://pubmed.ncbi.nlm.nih.gov/31105649/
  19. Bustos Fernandez LM, Man F, Lasa JS. Impact of Saccharomyces boulardii CNCM I-745 on Bacterial Overgrowth and Composition of Intestinal Microbiota in Diarrhea-Predominant Irritable Bowel Syndrome Patients: Results of a Randomized Pilot Study. Dig Dis. 2023;41(5):798-809. https://pubmed.ncbi.nlm.nih.gov/36630947/
  20. Preidis GA, Weizman AV, Kashyap PC, Morgan RL. AGA Technical Review on the Role of Probiotics in the Management of Gastrointestinal Disorders. Gastroenterology. 2020;159(2):708-738. https://pubmed.ncbi.nlm.nih.gov/32531292/
  21. Riaz M, Alam S, Malik A, Ali SM. Efficacy and safety of Saccharomyces boulardii in acute childhood diarrhea: a double blind randomised controlled trial. Indian J Pediatr. 2012;79(4):478-482. https://pubmed.ncbi.nlm.nih.gov/21997865/
  22. Vandenplas Y, Brunser O, Szajewska H. Saccharomyces boulardii in childhood. Eur J Pediatr. 2009;168(3):253-265. https://pubmed.ncbi.nlm.nih.gov/19096876/

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.